Dong Sung Pharmaceutical Minority Shareholders' Alliance: "Shareholder Value Must Not Be Undermined for the Sake of Normalization"... Calls for Financial Supervisory Service Investigation View original image

Minority shareholders of Dong Sung Pharmaceutical held a rally in front of the Financial Supervisory Service on March 13, arguing that the justification of normalizing the company should not be used as a means to legitimize the infringement of existing shareholders' rights.


They stressed that it must be clearly verified whether the rehabilitation plan and the acquisition efforts truly enhance the company's sustainability, or if they merely demand excessive sacrifices from minority shareholders.


The shareholders' alliance stated, "What is needed now is not the unconditional pursuit of M&A, but a transparent verification of which structure is genuinely beneficial for both shareholders and the company," and urged the Financial Supervisory Service to investigate whether minority shareholders are being harmed.



They further emphasized, "Rehabilitation should be a process that saves both the company and its stakeholders; it should not be a structure where only minority shareholders are unilaterally burdened with losses."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing